154 completed, 21 recruiting, 20 terminated, 11 unknown. 227 Phase 1, 49 Phase 2.
Follow Dermatitis, Atopic: new trials by email Literature Review of Dermatitis, Atopic trials Research Report on Dermatitis, Atopic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis baricitinib - Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2026-11-11 | 2026-11-06 |
| A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants GLR2053 Tablets, Placebo - Atopic Dermatitis | Phase 1 | Not yet recruiting | Gan & Lee Pharmaceuticals. | 124 | 2026-11-05 | 2026-11-06 |
| A Study of NOR-101 in Healthy Adults and Adults With Moderate-to-Severe Atopic Dermatitis NOR-101, Placebo - Atopic Dermatitis (AD) | Phase 1 | Not yet recruiting | North Immunology Inc. | 96 | 2026-11-01 | 2026-10-29 |
| A Study of HSK60002 Tablets in Participants With Moderate-to-Severe Atopic Dermatitis HSK60002 tablets, HSK60002 Placebo - Dermatitis Atopic | Phase 1 | Not yet recruiting | Haisco Pharmaceutical Group Co., Ltd. | 60 | 2026-11-01 | 2026-11-06 |
| Phase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe Atopic Dermatitis QX4533, QX4533 Placebo - Atopic Dermatitis | Phase 1 | Recruiting | QuantX Biosciences, Inc. | 84 | 2026-09-14 | 2026-10-02 |
| Study of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis HXN6005, Placebo - Health Adult Subjects, Atopic Dermatitis (AD) | Phase 1 / Phase 2 | Not yet recruiting | Helixon Biotechnology (Suzhou) Co., Ltd | 67 | 2026-09-01 | 2026-08-24 |
| A Study of BYN-001 in Healthy Adults and in Adults With Moderate to Severe Atopic Dermatitis BYN-001, Placebo - Atopic Dermatitis, Healthy Participants | Phase 1 | Recruiting | Bionyra Pharma | 56 | 2026-08-17 | 2026-09-30 |
| A Clinical Study of HRS-8797 in Healthy Participants HRS-8797, Placebo - Atopic Dermatitis | Phase 1 | Not yet recruiting | Chengdu Suncadia Medicine Co., Ltd. | 74 | 2026-07-01 | 2026-07-13 |
| A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis DCY636, Placebo - Dermatitis, Atopic | Phase 1 | Recruiting | Novartis Pharmaceuticals | 63 | 2026-06-02 | 2026-08-19 |
| Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease S-4321 - Autoimmune Diseases, Rheumatoid Arthritis (RA) | Phase 1 | Recruiting | Seismic Therapeutic AU Pty Ltd | 24 | 2026-06-01 | 2026-06-01 |
| A Dose Escalation Phase 1 Study of HXN5003 in Healthy Participants HXN5003, Placebo - Atopic Dermatitis | Phase 1 | Not yet recruiting | Helixon Biotechnology (Suzhou) Co., Ltd | 28 | 2026-05-27 | 2026-04-24 |
| HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis HL-300, Placebo - Atopic Dermatitis | Phase 1 / Phase 2 | Recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 156 | 2026-05-26 | 2026-06-23 |
| First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis REGN20423, Placebo - Healthy Volunteer, Atopic Dermatitis | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 160 | 2026-05-22 | 2026-11-06 |
| A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis IBI3033, Placebo - Atopic Dermatitis | Phase 1 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 16 | 2026-04-30 | 2026-04-24 |
| A Food Effect Study of VC005 Tablets in Healthy Adult Subjects. VC005 Tablets - Atopic Dermatitis | Phase 1 | Completed | Jiangsu vcare pharmaceutical technology co., LTD | 31 | 2026-04-23 | 2026-06-08 |
| A Phase 1 Study of Cizutamig in IgE Mediated Diseases Cizutamig - IgE-Mediated Hypersensitivity, IgE Mediated Food Allergy | Phase 1 | Withdrawn | Candid Therapeutics | 2026-04-01 | 2026-07-22 | |
| A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants SKB575 Injection/SKB575 Placebo - Atopic Dermatitis | Phase 1 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 90 | 2026-03-31 | 2026-05-08 |
| A Study on the Bioavailability of SHR-1819 Injection Administered Subcutaneously Using Different Injection Devices in Healthy Subjects SHR-1819 Injection - Atopic Dermatitis | Phase 1 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 160 | 2026-03-07 | 2026-08-24 |
| A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection GS101 injection, U.S. commercial Dupixent®, CN commercial Dupixent® - Atopic Dermatitis (AD) | Phase 1 | Completed | Jiangsu Genscend Biopharmaceutical Co., Ltd | 294 | 2026-03-05 | 2026-10-15 |
| Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 ARQ-234, Placebo - Atopic Dermatitis (AD), Eczema | Phase 1 | Recruiting | Arcutis Biotherapeutics, Inc. | 125 | 2026-03-02 | 2026-10-23 |
Showing 20 of 227. Sign in to see all of them.
Eczema (26) · Dermatitis (11) · Psoriasis (9) · Asthma (7) · Pruritus (6) · Skin Diseases (5) · Arthritis, Rheumatoid (3) · Hidradenitis Suppurativa (3) · Rhinitis, Allergic (3) · Urticaria (3) · Autoimmune Diseases (2) · Food Hypersensitivity (2) · Hypersensitivity, Immediate (2) · Pulmonary Disease, Chronic Obstructive (2)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (227) · Genetic Diseases, Inborn (227) · Skin and Connective Tissue Diseases (227) · Hypersensitivity (226) · Immune System Diseases (226) · Skin Diseases, Eczematous (226) · Skin Diseases, Genetic (226) · Hypersensitivity, Immediate (225) · Skin Diseases (222) · Dermatitis (216) · Pathological Conditions, Signs and Symptoms (11) · Respiratory Tract Diseases (11) · Respiratory Hypersensitivity (10) · Skin Diseases, Papulosquamous (9) · Bronchial Diseases (7)
dupilumab (5) · Midazolam (4) · 2-(6-(2-(3,5-dichloro-4-pyridyl)acetyl)-2,3-dimethoxyphenoxy)-N-propylacetamide (3) · Caffeine (3) · Clobetasol (3) · Metoprolol (3) · Ointments (3) · Omeprazole (3) · Warfarin (3) · abrocitinib (3) · GSK1070806 (2) · Injections, Subcutaneous (2) · Mometasone Furoate (2) · Omalizumab (2) · Tacrolimus (2)
LEO Pharma (14) · Pfizer (14) · National Institute of Allergy and Infectious Diseases (NIAID) (8) · GlaxoSmithKline (7) · Novartis Pharmaceuticals (5) · Regeneron Pharmaceuticals (5) · Amgen (4) · Jiangsu vcare pharmaceutical technology co., LTD (4) · Eli Lilly and Company (3) · Evelo Biosciences, Inc. (3) · Hangzhou Highlightll Pharmaceutical Co., Ltd (3) · Incyte Corporation (3) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (3) · AbbVie (2) · Arcutis Biotherapeutics, Inc. (2)
United States (90) · China (45) · Germany (22) · Australia (20) · Canada (16) · United Kingdom (15) · Japan (12) · New Zealand (8) · South Korea (7) · Belgium (6) · Netherlands (6) · Poland (5) · France (3) · Puerto Rico (3) · Spain (3)
Richard Gallo, M.D., Ph.D. (3) · David Berk, MD (2) · Duncan McHale, MD, PhD (2) · Henry Milgrom, M.D. (2) · Qianjin Lu (2)
PMID 18645136, PMID 22042247, PMID 23816920, PMID 24331381, PMID 25006719, PMID 25047038, PMID 25149431, PMID 25482871, PMID 25670894, PMID 26581111, PMID 26843086, PMID 27357167, PMID 27449926, PMID 29389078, PMID 29498038, PMID 29567358, PMID 31604104, PMID 32415720, PMID 32428543, PMID 32616515, PMID 33619370, PMID 33658996, PMID 35061234, PMID 35226304, PMID 35344588, PMID 35368221, PMID 35567671, PMID 36344555, PMID 36586583, PMID 37215725, PMID 37668898, PMID 37772436, PMID 37957373, PMID 38846687, PMID 39142926, PMID 39215351, PMID 39404994, PMID 39455575, PMID 39760983, PMID 40055981, PMID 40221092, PMID 41284735, PMID 41422501, PMID 42143645, PMID 42292382
2018 (6), 2014 (4), 2025 (2), 2017 (1), 2023 (1)